Assessment of Biomarkers in Patients With Decompensated Heart Failure and Underlying Coronary Artery Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Carol E Hendrix, MSN, RN
- Phone Number: 901-866-1700
- Email: chendrix@cirquestlabs.com
Study Contact Backup
- Name: Edward Hord, BSN, RN
- Phone Number: 901-866-1700
- Email: ehord@cirquestlabs.com
Study Locations
-
-
Florida
-
Jacksonville, Florida, United States, 32209
- Recruiting
- University of Florida
-
Contact:
- Latonya Been
- Phone Number: 904-244-4520
- Email: Latonya.Been@jax.ufl.edu
-
Principal Investigator:
- Dominick J Angiolillo, MD
-
-
Tennessee
-
Germantown, Tennessee, United States, 38138
- Recruiting
- Stern Cardiovascular
-
Contact:
- Brian Dragutsky
- Phone Number: 901-271-1000
- Email: brian.dragutsky@sterncardio.com
-
Contact:
- Rishi Bhula
- Phone Number: 901-271-1000
- Email: rishi.bhula@sterncardio.com
-
Principal Investigator:
- Frank A McGrew, MD
-
Memphis, Tennessee, United States, 38112
- Recruiting
- CirQuest Labs, LLC
-
Contact:
- Carol E Hendrix, MSN, RN
- Phone Number: 901-866-1700
- Email: chendrix@cirquestlabs.com
-
Contact:
- Edward Hord, BSN, RN
- Phone Number: 901-866-1700
- Email: ehord@cirquestlabs.com
-
Principal Investigator:
- Lisa K Jennings, PhD
-
Sub-Investigator:
- Rick Alleman, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Group 1: Heart Failure with Coronary Artery Disease Subjects
- Symptomatic heart failure (≥ 3 months) with most recently documented LVEF ≤ 40% (Echo must have been completed in last 12 months prior to enrollment.)
- Significant underlying coronary artery disease as evidenced by:
- previous myocardial infarction
- prior coronary artery bypass graft
- 50% coronary stenosis of one or more arteries and/or
- history of percutaneous coronary intervention with or without stenting
- Age 18 years or older at the first screening visit
Group 2: Healthy Subjects
• Age 18 years or older at the first screening visit and within 20% of mean age of Group 1 Subjects
Exclusion Criteria:
Group 1:
- Documented history of "severe" valvular disease
- Documented history of atrial fibrillation, ventricular fibrillation or ventricular tachycardia.
- Recent or current use of anticoagulant medications such as fXa inhibitors, direct thrombin inhibitors, vitamin K antagonists, or heparin. (within 1 month of screening)
Group 2:
- Known significant cardiovascular or hematological condition
- Recent or current use of anticoagulant medications such as fXa inhibitors, direct thrombin inhibitors, vitamin K antagonists, or heparin. (within 1 month of screening)
- Recent cold or flu symptoms, respiratory infection or surgery (within 2 weeks of screening)
- History of Asthma
- History of peptic ulcers
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Heart Failure & Coronary Artery Disease
Biomarker assessment in adults with decompensated heart failure and significant underlying coronary artery disease
|
Exploratory Biomarker Analysis for cardiac patients versus healthy adults
|
|
Healthy Adult
Biomarker assessment in 20 healthy age-matched subjects
|
Exploratory Biomarker Analysis for cardiac patients versus healthy adults
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Biomarker assessment
Time Frame: 1 day
|
Exploratory biomarker analysis
|
1 day
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Lisa K. Jennings, PhD, CirQuest Labs, LLC
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CQ 17-11-009
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.